Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 29 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)CompletedNCT02973997Phase 2Results posted
• Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain MetastasesActive, not recruitingNCT02971501Phase 2Results posted
• A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLActive, not recruitingNCT02970318Phase 3Results posted
• Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To MethotrexateCompletedNCT02969044Phase 2Results posted
• Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque PsoriasisCompletedNCT02969018Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT02968563Phase 2Results posted
• Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.CompletedNCT02966353Phase 2Results posted
• Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02965378Phase 2/3Results posted
• Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon CancerCompletedNCT02961374Phase 2Results posted
• Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)CompletedNCT02959944Phase 3Results posted
• Pharmacokinetics of Lanraplenib in Adults With Impaired Renal FunctionCompletedNCT02959138Phase 1Results posted
• Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative ColitisCompletedNCT02958865Phase 2Results posted
• Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaCompletedNCT02956382Phase 1/2Results posted
• A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)CompletedNCT02955212Phase 3Results posted
• Saracatinib and Alcohol DrinkingCompletedNCT02955186Phase 2Results posted
• Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerTerminatedNCT02954991Phase 2Results posted
• Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR MutationsTerminatedNCT02954523Phase 1/2Results posted
• A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)CompletedNCT02953678Phase 2Results posted
• Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic MutationsTerminatedNCT02949843Phase 2Results posted
• Study of Ibrutinib and Rituximab in Treatment Naïve Follicular LymphomaCompletedNCT02947347Phase 3Results posted
• Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma PatientsTerminatedNCT02943473Phase 2Results posted
• A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerCompletedNCT02937818Phase 2Results posted
• Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisCompletedNCT02931838Phase 2Results posted
• Ruxolitinib for Premalignant Breast DiseaseCompletedNCT02928978Phase 2Results posted
• TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaCompletedNCT02927964Phase 1/2Results posted
• A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete RemissionCompletedNCT02927262Phase 2Results posted
• A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic DermatitisCompletedNCT02925117Phase 2Results posted
• Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)CompletedNCT02924376Phase 2Results posted
• Merestinib In Non-Small Cell Lung Cancer And Solid TumorsTerminatedNCT02920996Phase 2Results posted
• A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced DiseaseCompletedNCT02915783Phase 2Results posted
• Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseTerminatedNCT02914600Phase 3Results posted
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseCompletedNCT02914561Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative ColitisCompletedNCT02914522Phase 3Results posted
• A Study of LY3337641 in Healthy Male ParticipantsCompletedNCT02914379Phase 1Results posted
• Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell TransplantationCompletedNCT02913261Phase 3Results posted
• Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT02910583Phase 2Results posted
• A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusCompletedNCT02908100Phase 2Results posted
• Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI FailureTerminatedNCT02906696Phase 2Results posted
• Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple MyelomaCompletedNCT02902965Phase 2Results posted
• Study of Nintedanib and Chemotherapy for Advanced Pancreatic CancerTerminatedNCT02902484Phase 1/2Results posted
• Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung CancerTerminatedNCT02899728Phase 2Results posted
• Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney CancerCompletedNCT02899078Phase 1/2Results posted
• Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung CancerCompletedNCT02898116Phase 1/2Results posted
• Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate CancerActive, not recruitingNCT02893917Phase 2Results posted
• A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune SuppressionCompletedNCT02891603Phase 1/2Results posted
• Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian CancerCompletedNCT02889900Phase 2Results posted
• Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateCompletedNCT02889796Phase 3Results posted
• Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX TherapyCompletedNCT02886728Phase 3Results posted
• Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in ChildrenTerminatedNCT02885324Phase 2Results posted
• Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With MethotrexateCompletedNCT02885181Phase 2Results posted
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsCompletedNCT02883049Phase 3Results posted
• A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid TumorsTerminatedNCT02880371Phase 1/2Results posted
• Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)CompletedNCT02878057Phase 2Results posted
• Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast CancerCompletedNCT02876302Phase 2Results posted
• TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02874404Phase 2Results posted
• Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) TreatmentCompletedNCT02873936Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)CompletedNCT02872714Phase 2Results posted
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantCompletedNCT02869633Phase 2Results posted
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruitingNCT02864992Phase 2Results posted
• Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)CompletedNCT02856893Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)CompletedNCT02853331Phase 3Results posted
• Study of Tesevatinib Monotherapy in Patients With Recurrent GlioblastomaCompletedNCT02844439Phase 2Results posted
• Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790MCompletedNCT02841579Phase 2Results posted
• A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02838420Phase 3Results posted
• Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02834780Phase 1Results posted
• Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02834390Phase 1Results posted
• A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT02834247Phase 1Results posted
• Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)CompletedNCT02833350Phase 2Results posted
• Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid ArthritisCompletedNCT02831855Phase 4Results posted
• A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid TumorsTerminatedNCT02829723Phase 1/2Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT02824029Phase 2Results posted
• Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaTerminatedNCT02819804Phase 1Results posted
• A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)CompletedNCT02819635Phase 2/3Results posted
• Topical Tofacitinib for the Treatment of Alopecia Areata and Its VariantsCompletedNCT02812342Phase 2Results posted
• Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaActive, not recruitingNCT02811861Phase 3Results posted
• Topical Ruxolitinib for the Treatment of VitiligoCompletedNCT02809976Phase 2Results posted
• A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy VolunteersCompletedNCT02804399Phase 1Results posted
• Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung CancersCompletedNCT02803203Phase 1/2Results posted
• A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02801578Phase 2/3Results posted
• Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell MalignanciesCompletedNCT02795182Phase 1Results posted
• Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsCompletedNCT02795156Phase 2Results posted
• Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy VolunteersCompletedNCT02792829Phase 1Results posted
• Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity ImpairmentCompletedNCT02788474Phase 4Results posted
• Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .CompletedNCT02788006Phase 2Results posted
• Long-Term Side Effects of Ruxolitinib in Treating Patients With MyelofibrosisCompletedNCT02784496Phase 2Results posted
• Safety and Efficacy Study of M2951 in Participants With Rheumatoid ArthritisCompletedNCT02784106Phase 2Results posted
• A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's DiseaseCompletedNCT02782663Phase 2Results posted
• Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]TerminatedNCT02780700Phase 2Results posted
• Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based ChemotherapyCompletedNCT02780687Phase 2Results posted
• Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic DermatitisCompletedNCT02780167Phase 2Results posted
• A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02774278Phase 2Results posted
• Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung CancerTerminatedNCT02770014Phase 2Results posted
• Expansion Trial for Axitinib In Head And Neck CancerCompletedNCT02762513Phase 2Results posted
• Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedNCT02761057Phase 2Results posted
• A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02760485Phase 1/2Results posted
• Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With OsimertinibCompletedNCT02759835Phase 2Results posted
• Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02759731Phase 1/2Results posted
• A Study of Baricitinib (LY3009104) in Healthy Chinese ParticipantsCompletedNCT02758613Phase 1Results posted
• A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard ChemotherapyCompletedNCT02752035Phase 3Results posted

← Tyrosine Kinase Inhibitors overview